Bio-Techne (TECH) Declares $0.32 Quarterly Dividend; 0.5% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bio-Techne (TECH) Tops Q4 EPS by 25c
August 4, 2020 6:31 AM EDTBio-Techne (NASDAQ: TECH) reported Q4 EPS of $1.00, $0.25 better than the analyst estimate of $0.75. Revenue for the quarter came in at $175.8 million versus the consensus estimate of $163.91 million.
For earnings history and earnings-related data on Bio-Techne (TECH) click here.
... MoreBio-Techne (TECH) Adds Julie L. Bushman to Board
August 3, 2020 7:09 AM EDTBio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Julie L. Bushman to serve as an independent director on the company's board of directors, effective as of July 31, 2020. Following the appointment, the board of Bio-Techne will be comprised of ten directors, nine of... More
Bio-Techne (TECH) And Kantaro Biosciences To Launch A Quantitative Research Use Only COVID-19 Serology Test
August 3, 2020 7:07 AM EDTBio-Techne Corporation (NASDAQ: TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available for research use in early August.
The COVID-SeroIndex test kit is an enzyme-linked immunosorbent assay, or ELISA, designed to measure the presence or... More
